Recurrent or stage IVB cervical cancer research hub

A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer

This study is testing a new medicine called tisotumab vedotin for advanced cervical cancer that has come back or spread. It looks at how safe the medicine is by itself and when given with other common cancer drugs, and how well it works to shrink tumours.